نتایج جستجو برای: mf59

تعداد نتایج: 256  

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2016
Helder I Nakaya Elizabeth Clutterbuck Dmitri Kazmin Lili Wang Mario Cortese Steven E Bosinger Nirav B Patel Daniel E Zak Alan Aderem Tao Dong Giuseppe Del Giudice Rino Rappuoli Vincenzo Cerundolo Andrew J Pollard Bali Pulendran Claire-Anne Siegrist

The dynamics and molecular mechanisms underlying vaccine immunity in early childhood remain poorly understood. Here we applied systems approaches to investigate the innate and adaptive responses to trivalent inactivated influenza vaccine (TIV) and MF59-adjuvanted TIV (ATIV) in 90 14- to 24-mo-old healthy children. MF59 enhanced the magnitude and kinetics of serum antibody titers following vacci...

2013
Theodore F Tsai

Influenza directly or indirectly contributes to the four leading causes of global mortality, at rates that are highest in older adults. As the proportion of older adults in the Korean population is greater than in most other countries, influenza prevention is a greater public health priority in Korea than elsewhere. Conventional inactivated influenza vaccine (IIV) is less immunogenic and effica...

Journal: :The Journal of infectious diseases 2005
Iain Stephenson Roberto Bugarini Karl G Nicholson Audino Podda John M Wood Maria C Zambon Jacqueline M Katz

Antigenically well-matched vaccines against highly pathogenic avian influenza H5N1 viruses are urgently required. Human serum samples after immunization with MF59 or nonadjuvanted A/duck/Singapore/97 (H5N3) vaccine were tested for antibody to 1997-2004 human H5N1 viruses. Antibody responses to 3 doses of nonadjuvanted vaccine were poor and were higher after MF59-adjuvanted vaccine, with serocon...

Journal: :Clinical and vaccine immunology : CVI 2010
Elena Fragapane Roberto Gasparini Francesco Schioppa Franco Laghi-Pasini Emanuele Montomoli Angelika Banzhoff

Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 μg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.

Journal: :Human Vaccines & Immunotherapeutics 2018

2011
David N. Fisman Ashleigh R. Tuite

INTRODUCTION The propensity for influenza viruses to mutate and recombine makes them both a familiar threat and a prototype emerging infectious disease. Emerging evidence suggests that the use of MF59-adjuvanted vaccines in older adults and young children enhances protection against influenza infection and reduces adverse influenza-attributable outcomes compared to unadjuvanted vaccines. The he...

2013
Eva M Riedmann

Agenus brain cancer vaccine improves survival in phase 2 trial: Meningococcal meningitis cases fall 94% following vaccine introduction: Most vaccines are safe during breastfeeding: Promising phase 1 results for Genocea's herpes simplex virus vaccine: Delayed vaccinations clearly increase risk of whooping cough: Positive news from early-stage HIV vaccines: Sanofi's H7N9 vaccine trial with MF59 a...

2016
Glenda E. Gray Kenneth H. Mayer Marnie L. Elizaga Linda-Gail Bekker Mary Allen Lynn Morris David Montefiori Stephen C. De Rosa Alicia Sato Niya Gu Georgia D. Tomaras Timothy Tucker Susan W. Barnett Nonhlanhla N. Mkhize Xiaoying Shen Katrina Downing Carolyn Williamson Michael Pensiero Lawrence Corey Anna-Lise Williamson

A phase I safety and immunogenicity study investigated South African AIDS Vaccine Initiative (SAAVI) HIV-1 subtype C (HIV-1C) DNA vaccine encoding Gag-RT-Tat-Nef and gp150, boosted with modified vaccinia Ankara (MVA) expressing matched antigens. Following the finding of partial protective efficacy in the RV144 HIV vaccine efficacy trial, a protein boost with HIV-1 subtype C V2-deleted gp140 wit...

2017

Modelling A cohort model was used to assess the costs and consequences of adjuvanted vaccine against influenza in comparison with standard non-adjuvanted vaccination in the high-risk elderly. The model considered the attack rate in the relevant population, and subsequent cases, general practitioner (GP) visits, hospital admissions and deaths. Adverse events were not considered. The time horizon...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید